Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.

Masatoshi EtoToshio TakagiGo KimuraSatoshi FukasawaSatoshi TamadaYuji MiuraMototsugu OyaNaoto SassaSatoshi AnaiMasahiro NozawaHideki SakaiRodolfo PeriniWataru YusaHiroki IkezawaTomoyuki NaritaYoshihiko Tomita

Published in: Cancer medicine (2022)

These findings support lenvatinib plus pembrolizumab as a potential first-line treatment for Japanese patients with advanced renal cell carcinoma.

Keyphrases

renal cell carcinoma
advanced non small cell lung cancer
climate change